Evommune, Inc.
No enriched coverage for $EVMN in the last 7 days.
No SEC Form 4 filings for $EVMN in the last 30 days.
See all $EVMN insider activity →Evommune (NYSE:EVMN) presented Phase 2a trial data for EVO301 in atopic dermatitis, showing a 55% reduction in EASI score vs. 22% on placebo. The trial met its primary endpoint, with significant improvements observed at multiple time points. The company plans to initiate a Phase 2b trial in mid-2027.
Evommune, Inc. (EVMN) filed an SEC Form 8-K — Regulation FD Disclosure. Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress - Presentation highlights EVO301’s clear therapeutic signal, favorable safety and tolerability profile, and reinforces
Evommune (EVMN) announced positive Phase 2a data for EVO301 in treating moderate-to-severe atopic dermatitis. The results will be presented at the European Academy of Dermatology & Venereology Congress on October 1, 2026, highlighting EVO301's potential as a broad-spectrum inflammatory treatment.
Recent EVMN coverage spans financial news, technology and corporate actions.
Positive trial results are likely to lift the stock as investors anticipate further development and potential market approval.
Positive trial results suggest near‑term upside as investors price in potential market approval and future Phase 2b launch.
Positive early‑stage data could lift the stock as investors reassess the drug's potential and upcoming milestones.
Positive Phase 2a data could validate the IL-18 pathway and drive near‑term share interest ahead of the presentation.
The filing adds no new quantitative guidance or material event; it reiterates existing expectations.
AlphAI scores every news story that mentions EVMN with an AI model for sentiment and relevance, and aggregates insider trades from Evommune, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Evommune (NYSE:EVMN) presented Phase 2a trial data for EVO301 in atopic dermatitis, showing a 55% reduction in EASI score vs. 22% on placebo. The trial met its primary endpoint, with significant improvements observed at multiple time points. The company plans to initiate a Phase 2b trial in mid-2027.
2 min readEvommune, Inc. (EVMN) filed an SEC Form 8-K — Regulation FD Disclosure. Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress - Presentation highlights EVO301’s clear therapeutic signal, favorable safety and tolerability profile, and reinforces
3 min readEvommune (EVMN) announced positive Phase 2a data for EVO301 in treating moderate-to-severe atopic dermatitis. The results will be presented at the European Academy of Dermatology & Venereology Congress on October 1, 2026, highlighting EVO301's potential as a broad-spectrum inflammatory treatment.
1 min readEvommune, Inc. (EVMN) filed an SEC Form 8-K — Regulation FD Disclosure. Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress Palo Alto, Calif., and New York, September 23, 2026 – Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical
2 min readEvommune, Inc. (EVMN) filed an SEC Form 8-K — Regulation FD Disclosure. Evommune Corporate Presentation September 2026 © Evommune, Inc. Disclaimers This presentation has been prepared by Evommune, Inc. (“we”, “us” or “our”) and contains forward-looking statements, including: statements about our expectations regarding the potential benefits, clinical
1 min readEvommune's (EVMN) stock fell 53% after its eczema treatment failed midstage trials, following a previous failure in treating hives. The company continues testing EVO756 for migraine prevention and has another eczema treatment, EVO301, in development.
1 min readUS equity futures fell as Brent crude oil topped $100, pushing 10-year Treasury yields above 4.81%. Meta (META) rose 5% on strong AI usage, while other Mag 7 stocks traded mixed. Braze (BRZE) dropped 11% on weak earnings forecasts, and ServiceTitan (TTAN) fell 17% on revenue concerns. Chime (CHYM) gained 9% after acquiring Stride Bank. Oil prices surged after US strikes on Iranian tankers, and Treasury Secretary Scott Bessent challenged traders on yen strength. Barclays raised its S&P 500 target
3 min readEvommune Inc (EVMN) shares dropped 27% after its EVO756 drug failed to meet primary and secondary endpoints in a Phase 2b trial for atopic dermatitis. The trial involved 121 adults over 12 weeks. Evommune will not advance EVO756 for this indication but will continue its development for migraine prophylaxis. The company plans to advance EVO301 for atopic dermatitis, with a Phase 2b trial expected in mid-2027. Evommune reports a strong balance sheet supporting operations into 2029.
2 min readAnalysts initiated coverage on several companies: Needham rated Evommune (EVMN) Buy with a $28 target, Daiwa rated ACM Research (ACMR) Buy with a $136 target, Wolfe Research rated Harmony Biosciences (HRMY) Outperform with a $60 target, RBC rated Atlassian (TEAM) Outperform with a $215 target, and RBC rated JFrog (FROG) Outperform with a $118 target.
2 min readEvommune, Inc. (EVMN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights ‑ Company to announce EVO756 atopic dermatitis (AD) Phase 2b top-line data in September 2026 ‑ EVO756 migraine prophylaxis Phase 2b dose-ranging trial recently initiated with top-line data in
4 min read
